CBLB Antibodies

Structure of CBLB

The protein encoded by the CBLB gene has a molecular weight of approximately 110 kDa, and there are certain differences among different species. This protein is composed of about 980 amino acids and includes multiple functional domains such as the tyrosine kinase binding domain, the helix-loop-helix domain, and the proline-rich region. As an E3 ubiquitin ligase, CBLB mediates the ubiquitination modification of substrate proteins through its helix-loop-helix domain, thereby regulating the signal transduction of immune receptors. Its SH2 domain is responsible for recognizing phosphorylated tyrosine residues and mediating specific binding with upstream signaling molecules. This protein is widely expressed in immune cells and plays a crucial regulatory role in maintaining immune tolerance and preventing autoimmune reactions.

Fig. 1 Ribbon diagram of the human CBL-B TKB and RING domains.¹

Key structural features of CBLB protein:

• The N-terminal tyrosine kinase binding domain mediates substrate recognition
• The loop finger domain confers E3 ubiquitin ligase activity
• The proline-rich region is involved in the protein interaction network
• The conserved leucine zipper-like sequence regulates dimerization
• Multiple phosphorylation sites sense the dynamic upstream signals

Functions of CBLB

The protein encoded by the CBLB gene acts as an E3 ubiquitin ligase and mainly maintains immune homeostasis by negatively regulating immune signal transduction. Its core functions involve multiple physiological processes:

Compared with the other member of the CBL family, c-CBL, CBL-B is expressed at a higher level in immune cells and has stronger functional specificity. Its absence can lead to autoimmune disorders in multiple organs.

Applications of CBLB and CBLB Antibody in Literature

1. Janssen, Erin, et al. "Immune dysregulation caused by homozygous mutations in CBLB." The Journal of Clinical Investigation 132.20 (2022). https://doi.org/10.1172/JCI154487

The article indicates that the CBL-B gene mutation leads to immune dysregulation: the T cells of the patients proliferate excessively, and the effector cells resist the inhibition of regulatory T cells. The mouse model confirmed that the mutation causes excessive activation of T/B cells and mast cells, exacerbating allergic reactions. This study establishes CBL-B deficiency as a new mechanism for autoimmune diseases.

2. Zhang, Mengyu, et al. "Exosome circ-CBLB promotes M1 macrophage polarization in rheumatoid arthritis through the TLR3/TRAF3 signaling axis." Frontiers in Immunology 16 (2025): 1627389. https://doi.org/10.3389/fimmu.2025.1627389

The article indicates that the expression of circ-CBLB in patients with rheumatoid arthritis is decreased, and it is negatively correlated with immune-inflammatory indicators. Circ-CBLB inhibits the TLR3/TRAF3 pathway by binding to TLR3, and reduces the polarization of M1-type macrophages. Exosomes of circ-CBLB are involved in disease regulation and provide new ideas for diagnosis and treatment.

3. You, Hongjun, et al. "Exploring the role of CBLB in acute myocardial infarction: transcriptomic, microbiomic, and metabolomic analyses." Journal of translational medicine 22.1 (2024): 654. https://doi.org/10.1186/s12967-024-05425-y

The article indicates that after CBLB intervention in acute myocardial infarction mice, the infiltration of myocardial inflammation was alleviated. Multimodal analysis revealed that CBLB was significantly correlated with different genes, metabolites, and gut microbiota, suggesting that it regulates the myocardial infarction process from multiple aspects and provides new targets for treatment.

4. Yan, Dawei, and Lei Wan. "WTAP modulates macrophage polarization in rheumatoid arthritis by targeting exosomal circ-CBLB via m6A modification." Frontiers in Immunology 16 (2025): 1601259. https://doi.org/10.3389/fimmu.2025.1601259

The article indicates that the exosomes derived from rheumatoid arthritis synovial fibroblasts, circ-CBLB, are regulated by m6A modification mediated by WTAP for degradation, and the reduction of this process promotes the polarization of macrophages towards the pro-inflammatory M1 type. The WTAP-circ-CBLB axis may serve as a new therapeutic target.

5. Zhou, Hekai, et al. "Postoperative circulating tumor DNA detection and CBLB mutations are prognostic biomarkers for gastric cancer." Genes & Genomics 45.8 (2023): 1037-1046. https://doi.org/10.1007/s13258-023-01412-7

The article indicates that positive ctDNA in gastric cancer patients is associated with a higher TNM stage, poor therapeutic effect, and worse prognosis. The analysis of the TCGA database shows that the overall survival and progression-free survival of patients with CBLB gene mutations are significantly shorter than those of the wild-type, suggesting that CBLB may be a prognostic marker for gastric cancer.

Creative Biolabs: CBLB Antibodies for Research

Creative Biolabs specializes in the production of high-quality CBLB antibodies for research and industrial applications. Our portfolio includes monoclonal and polyclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom CBLB Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our CBLB antibodies, custom preparations, or technical support, contact us at email.